Article
SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker - Oncogene
Rating:
0.0
Views:
65
Likes:
1
Library:
1
SHP1, a tyrosine phosphatase, negatively regulates B-cell receptor (BCR) signaling. Ibrutinib selectively inhibits BTK and has been approved for the treatment of several types of B-cell lymphomas, but not yet in diffuse large B-cell lymphoma (DLBCL). A phase 3 clinical trial of ibrutinib–containing regimen has been completed to evaluate its activity in subtypes or subsets of DLBCL patients.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value